AimTo evaluate the levels of plasma lipoprotein associated phospholipase A2 (Lp-LPA2) in patients with coronary heart disease(CHD) and provide effective biomarkers for early diagnosis of acute coronary syndrome (ACS).Methods230 subjects with angiographic inpatients were didvided into three groups: ACS group with 98 cases, Non-ACS group with 81 cases, and normal cornary artery group (NCA) as control with 51 cases.ACS group included unstable angina pectoris (UAP) subgroup with 61 patients and acute myocardial infarction (AMI) subgroup with 37 patients; Non-ACS group included stable angina pectoris (SAP) subgroup with 49 cases and chronic total occlusion (CTO) subgroup with 32 patients.Plasma concentrations of Lp-LPA2 in all individuals were measured using commercial kit by enzyme linked immunosorbent assay (ELISA).ResultsLp-LPA2 and hs-CRP levels were significantly higher in CHD patients including ACS and Non-ACS groups than in NCA group (p<0.001).ACS group showed very significantly higher Lp-LPA2 levels (p<0.001) and higher hs-CRP level(p<0.05) than Non-ACS group.Compared with NCA gro-up, subgroups including UAP, AMI, and CTO subgroup showed obvious increases in plasma Lp-LPA2 levels (p<0.001), and SAP subgroup showed no significant increase (p>0.05).Hs-CRP level was significantly higher in every subgroup (p<0.001).ConclusionsElevated Lp-LPA2 levels in CHD patients suggest the instability of atherosclerotic plaque and may be viewed as aneffective indicator for prediction of ACS.